1,029,478 Shares in Design Therapeutics, Inc. (NASDAQ:DSGN) Acquired by BML Capital Management LLC

BML Capital Management LLC bought a new position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,029,478 shares of the company’s stock, valued at approximately $2,728,000. Design Therapeutics makes up approximately 2.1% of BML Capital Management LLC’s investment portfolio, making the stock its 12th biggest position. BML Capital Management LLC owned 1.84% of Design Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of DSGN. Nisa Investment Advisors LLC grew its position in Design Therapeutics by 38,433.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 11,560 shares of the company’s stock valued at $31,000 after acquiring an additional 11,530 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Design Therapeutics in the third quarter valued at approximately $47,000. Corton Capital Inc. grew its position in Design Therapeutics by 56.6% in the third quarter. Corton Capital Inc. now owns 27,134 shares of the company’s stock valued at $64,000 after acquiring an additional 9,811 shares in the last quarter. Algert Global LLC grew its position in Design Therapeutics by 83.3% in the third quarter. Algert Global LLC now owns 35,620 shares of the company’s stock valued at $84,000 after acquiring an additional 16,190 shares in the last quarter. Finally, Jump Financial LLC grew its position in Design Therapeutics by 284.7% in the third quarter. Jump Financial LLC now owns 46,700 shares of the company’s stock valued at $110,000 after acquiring an additional 34,561 shares in the last quarter. Institutional investors and hedge funds own 56.64% of the company’s stock.

Insider Buying and Selling

In other news, Director John P. Schmid acquired 17,809 shares of Design Therapeutics stock in a transaction that occurred on Monday, March 25th. The shares were purchased at an average cost of $3.74 per share, for a total transaction of $66,605.66. Following the completion of the purchase, the director now directly owns 26,965 shares of the company’s stock, valued at approximately $100,849.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director John P. Schmid bought 17,809 shares of the company’s stock in a transaction on Monday, March 25th. The shares were purchased at an average cost of $3.74 per share, with a total value of $66,605.66. Following the completion of the transaction, the director now directly owns 26,965 shares of the company’s stock, valued at $100,849.10. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director John P. Schmid bought 9,156 shares of the company’s stock in a transaction on Friday, March 22nd. The stock was bought at an average cost of $3.62 per share, for a total transaction of $33,144.72. Following the completion of the transaction, the director now directly owns 9,156 shares of the company’s stock, valued at $33,144.72. The disclosure for this purchase can be found here. 25.70% of the stock is currently owned by company insiders.

Design Therapeutics Trading Down 5.9 %

Design Therapeutics stock opened at $3.66 on Wednesday. The stock has a market cap of $206.75 million, a P/E ratio of -3.05 and a beta of 1.82. The stock has a 50 day moving average of $3.23 and a 200-day moving average of $2.65. Design Therapeutics, Inc. has a 52 week low of $1.94 and a 52 week high of $8.47.

Design Therapeutics (NASDAQ:DSGN) last released its earnings results on Tuesday, March 19th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.11. As a group, equities analysts predict that Design Therapeutics, Inc. will post -1.25 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

DSGN has been the subject of several recent research reports. Wedbush reaffirmed a “neutral” rating and issued a $5.00 price objective on shares of Design Therapeutics in a research report on Wednesday, March 20th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $4.00 price objective on shares of Design Therapeutics in a research report on Wednesday, March 20th. Seven equities research analysts have rated the stock with a hold rating, According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $5.50.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.